Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin vs ALLR3 in pediatric relapsed B-cell precursor ALL
NCT05748171Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- May 2023
- Primary completion
- May 2033
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Pfizer. Primary endpoint: Minimum Residual Disease Negativity at Day 28. Started May 2023; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05748171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748171.